Abstract:

Objective To evaluate the efficacy of Entecavir（ETV）combined with Wuling Capsule for chronic hepatitis B（CHB）patients. Methods Data of 117 CHB patients were collected from the Second Affiliated Hospital，Guangzhou Medical University from April 2019 and September 2020. Sixty ⁃two patients received ETV 0.5 mg/d + Wuling Capsule 1.75 g/d（treatment group）and 55 patients received ETV 0.5 mg/d（control group）for 24 weeks. Biochemical and virological indexes during the treatment were collected. The differences of liver function indexes at baseline，the 4th week，the 12th week，and the 24th week were studied by repeated measures analysis of variance，while the differences in the normalization rate of liver function，decrease of liver fibrosis，HBV DNA negative conversion rates and HBeAg negative conversion rates between treatment group and control group were evaluated by independent samples t test，Mann⁃Whitney U test，and chi⁃square test. The factors of normalization of liver function was evaluated by logistic regression. The median time to cumulativly achieve normal ALT level was evaluated by Kaplan⁃Meier. Results The decrease of ALT，AST level at the 4th week，the 12th week，and the 24th week after treatment was statistically significant when compared with that of the control group（P < 0.05）. The most significantly decrease of ALT，and AST level occurred at the 4th week. The decrease of TBIL level and liver fibrosis （HA，LN，IV⁃C and PIIINP levels）were statistically significant when compared with the control group（P < 0.05）. In treatment group，the ALT，AST and TBIL normalization rate at the 24th week was 90.3%，80.6% and 48.3% respectively，significantly higher than that of the control group（P < 0.05）. Logistic regression analysis found that the treatment group was protective factor correlated with ALT，AST and TBIL normalization rate（ORALT=12.056， P＜0.05、OR AST = 8.56，P＜0.05，ORTBIL=2.58，P＜0.05）. HBV DNA negative conversion rate and HBeAg negative conversion rate in the treatment group were not statistically significant when compared with those in the control group（χ2 = 3.81，P > 0.05；χ2 = 2.23，P > 0.05）. The median time to cumulatively achieve normal ALT level were 24 weeks in the treatment group and 36 weeks in the control group（P＜0.05）. Conclusions Faster and better recovery of liver function can be achieved through Entecavir（ETV）combined with Wuling Capsule for CHB patients，which provides effective new evidence to optimize the outcomes for the re ⁃ combination of current medicine.

Key words:

chronic hepatitis B, Entecavir, Wuling Capsule, liver function, antiviral